Published in Dis Model Mech on September 03, 2009
Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer. J Clin Oncol (2014) 1.79
Systemic therapies for pancreatic cancer--the role of pharmacogenetics. Curr Drug Targets (2012) 0.86
The use of genomic information to optimize cancer chemotherapy. Semin Oncol (2011) 0.84
Can knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy? Biomark Med (2012) 0.77
One SNP for both cancer risk and survival in colorectal cancer: two for the price of one? Pharmacogenomics (2012) 0.75
Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study. Pharmacogenomics J (2015) 0.75
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol (2003) 9.72
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol (2010) 5.21
Processes to activate phase III clinical trials in a Cooperative Oncology Group: the Case of Cancer and Leukemia Group B. J Clin Oncol (2006) 4.91
American Society of Clinical Oncology Statement on minimum standards and exemplary attributes of clinical trial sites. J Clin Oncol (2008) 4.79
Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol (2006) 4.27
American Society of Clinical Oncology 2013 top five list in oncology. J Clin Oncol (2013) 4.03
Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res (2005) 3.71
American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol (2014) 3.20
Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. J Clin Oncol (2009) 2.40
Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344). J Natl Cancer Inst (2006) 2.34
Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists. J Clin Oncol (2013) 2.20
Ethnic differences and functional analysis of MET mutations in lung cancer. Clin Cancer Res (2009) 2.03
Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol (2006) 1.93
The impact of the privacy rule on cancer research: variations in attitudes and application of regulatory standards. J Clin Oncol (2009) 1.88
Construct validity of medicare chemotherapy claims: the case of 5FU. Med Care (2002) 1.87
Ethical, scientific, and regulatory perspectives regarding the use of placebos in cancer clinical trials. J Clin Oncol (2008) 1.71
Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants. J Natl Cancer Inst (2005) 1.70
Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2008) 1.69
Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2006) 1.64
Optimizing collection of adverse event data in cancer clinical trials supporting supplemental indications. J Clin Oncol (2010) 1.63
A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Cancer Res (2005) 1.62
Oncology physician and nurse practices and attitudes regarding offering clinical trial results to study participants. J Natl Cancer Inst (2004) 1.51
A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903. Ann Surg Oncol (2007) 1.46
Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward. Clin Cancer Res (2010) 1.44
Ethics of mandatory research biopsy for correlative end points within clinical trials in oncology. J Clin Oncol (2010) 1.42
Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism. Clin Cancer Res (2003) 1.37
Breaking a vicious cycle. Sci Transl Med (2013) 1.36
Role of randomized phase III trials in an era of effective targeted therapies. Nat Rev Clin Oncol (2011) 1.33
A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine. Clin Pharmacol Ther (2003) 1.31
Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. J Natl Cancer Inst (2010) 1.30
Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. J Clin Oncol (2009) 1.28
Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2007) 1.28
Clinical pharmacology and pharmacogenetics of gemcitabine. Drug Metab Rev (2009) 1.27
Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581. J Clin Oncol (2013) 1.27
A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303. Clin Cancer Res (2011) 1.26
Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines. Clin Cancer Res (2007) 1.20
Insights, challenges, and future directions in irinogenetics. Ther Drug Monit (2007) 1.17
Molecular markers to individualize adjuvant therapy for colon cancer. Nat Rev Clin Oncol (2010) 1.17
The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity. J Clin Pharmacol (2007) 1.16
Clinical trials in the era of personalized oncology. CA Cancer J Clin (2011) 1.13
Hurry up and wait: is accelerated approval of new cancer drugs in the best interests of cancer patients? J Clin Oncol (2003) 1.13
A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603). Oncologist (2010) 1.10
Effect of methylenetetrahydrofolate reductase 677C-->T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients. Int J Cancer (2003) 1.08
Biological, clinical, and psychosocial correlates at the interface of cancer and aging research. J Natl Cancer Inst (2012) 1.07
UGT pharmacogenomics: implications for cancer risk and cancer therapeutics. Pharmacogenetics (2003) 1.07
The role of pharmacogenetics in cancer therapeutics. Br J Clin Pharmacol (2006) 1.06
Searching for tissue-specific expression pattern-linked nucleotides of UGT1A isoforms. PLoS One (2007) 1.05
Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer. Clin Cancer Res (2011) 1.05
The cancer and leukemia group B pharmacology and experimental therapeutics committee: a historical perspective. Clin Cancer Res (2006) 1.05
Designing therapeutic clinical trials for older and frail adults with cancer: U13 conference recommendations. J Clin Oncol (2014) 1.04
A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661. Clin Cancer Res (2002) 1.02
Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue. Clin Cancer Res (2004) 1.01
End points in cancer clinical trials and the drug approval process. Clin Cancer Res (2002) 0.98
Reevaluating the accelerated approval process for oncology drugs. Clin Cancer Res (2013) 0.98
Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin Cancer Res (2004) 0.98
Using patient-initiated study participation in the development of evidence for personalized cancer therapy. Clin Cancer Res (2011) 0.97
Measuring clinically significant chemotherapy-related toxicities using Medicare claims from Cancer and Leukemia Group B (CALGB) trial participants. Med Care (2008) 0.96
Implications of genome-wide association studies in cancer therapeutics. Br J Clin Pharmacol (2013) 0.96
Colorectal adenomas: a prototype for the use of surrogate end points in the development of cancer prevention drugs. Clin Cancer Res (2004) 0.96
Effects of ketoconazole on glucuronidation by UDP-glucuronosyltransferase enzymes. Clin Cancer Res (2005) 0.95
A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours. Eur J Cancer (2008) 0.94
Cancer and Leukemia Group B Pathology Committee guidelines for tissue microarray construction representing multicenter prospective clinical trial tissues. J Clin Oncol (2011) 0.94
Lack of association between common polymorphisms in UGT1A9 and gene expression and activity. Drug Metab Dispos (2007) 0.93
In vitro characterization of hepatic flavopiridol metabolism using human liver microsomes and recombinant UGT enzymes. Pharm Res (2002) 0.93
Toward efficient trials in colorectal cancer: the ARCAD Clinical Trials Program. J Clin Oncol (2009) 0.92
A genome-wide integrative study of microRNAs in human liver. BMC Genomics (2013) 0.92
Irinogenetics: what is the right star? J Clin Oncol (2006) 0.91
Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens. J Pharmacol Exp Ther (2013) 0.91
Pharmacogenomics: road to anticancer therapeutics nirvana? Oncogene (2003) 0.90
Discovery and functional assessment of gene variants in the vascular endothelial growth factor pathway. Hum Mutat (2013) 0.89
UGT1A1*28 genotype affects the in-vitro glucuronidation of thyroxine in human livers. Pharmacogenet Genomics (2007) 0.88
Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet? Pharmacotherapy (2008) 0.88
Refocusing the war on cancer: the critical role of personalized treatment. Sci Transl Med (2010) 0.87
Mechanisms of genetic regulation in gene expression: examples from drug metabolizing enzymes and transporters. Wiley Interdiscip Rev Syst Biol Med (2010) 0.87
Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients. Clin Cancer Res (2013) 0.87
Systemic therapies for pancreatic cancer--the role of pharmacogenetics. Curr Drug Targets (2012) 0.86
CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes. Drug Metab Dispos (2004) 0.86
Individualizing dosing of irinotecan. Clin Cancer Res (2010) 0.86
A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital. Clin Pharmacol Ther (2004) 0.86
Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer. Cancer Chemother Pharmacol (2007) 0.84
Study of the genetic determinants of UGT1A1 inducibility by phenobarbital in cultured human hepatocytes. Pharmacogenet Genomics (2006) 0.84
Estimation of the effect of food on the disposition of oral 5-fluorouracil in combination with eniluracil. Cancer Chemother Pharmacol (2002) 0.84
WIN Consortium--challenges and advances. Nat Rev Clin Oncol (2011) 0.84
Pharmacogenomics: paving the path to personalized medicine. Pharmacogenomics (2010) 0.84
The influence of UGT polymorphisms as biomarkers in solid organ transplantation. Clin Chim Acta (2012) 0.83
Randomized controlled trials and comparative effectiveness research. J Clin Oncol (2012) 0.83
Liver expression quantitative trait loci: a foundation for pharmacogenomic research. Front Genet (2012) 0.82
Institutional Profile: Golden Helix Institute of Biomedical Research: interdisciplinary research and educational activities in pharmacogenomics and personalized medicine. Pharmacogenomics (2012) 0.82
Patient advocates' role in clinical trials: perspectives from Cancer and Leukemia Group B investigators and advocates. Cancer (2012) 0.82
GI cancers in 2010: New standards and a predictive biomarker for adjuvant therapy. Nat Rev Clin Oncol (2011) 0.81
Strategies to overcome clinical, regulatory, and financial challenges in the implementation of personalized medicine. Am Soc Clin Oncol Educ Book (2013) 0.81
Functional FLT1 Genetic Variation is a Prognostic Factor for Recurrence in Stage I-III Non-Small-Cell Lung Cancer. J Thorac Oncol (2015) 0.81
A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors. Clin Cancer Res (2004) 0.81